Management of Follicular Neoplasm (Bethesda IV) on FNAC
The American Thyroid Association (ATA) recommends diagnostic surgical excision as the long-established standard of care for Bethesda IV (follicular neoplasm/suspicious for follicular neoplasm [FN/SFN]) thyroid nodules. [1]
After consideration of clinical and sonographic features, molecular marker testing may be used to supplement malignancy risk assessment in lieu of proceeding directly with surgery. [1]
If molecular testing is not performed or is inconclusive, surgical excision may be considered for removal and definitive diagnosis. [1]
Medication Selection Algorithm
No medication is recommended as a primary management strategy for Bethesda IV FNAC results. [1]
Key Evidence Supporting This Recommendation
Bethesda IV (FN/SFN) cytology has an estimated malignancy risk of 15%–30%. [1]
Monotherapy Versus Combination Therapy
Molecular marker testing is used to supplement malignancy risk assessment rather than to replace clinical and sonographic risk assessment. [1]
Surgical excision is used for definitive diagnosis when molecular testing is not performed or is inconclusive. [1]
Important Clarifications or Nuances
The ATA notes that informed patient preference and feasibility should be considered in clinical decision-making when choosing between molecular testing and direct surgery. [1]
Initiation Thresholds or Indications
Molecular marker testing may be used to supplement risk assessment after consideration of clinical and sonographic features. [1]
When molecular testing is not performed or results are inconclusive, surgical excision may be considered for definitive diagnosis. [1]
Common Pitfalls to Avoid
Assuming that Bethesda IV cytology is diagnostic of malignancy is not supported. [1]
Relying on molecular testing alone without incorporating clinical and sonographic risk assessment is not supported. [1]
Targets or Goals of Therapy
The management goal is definitive diagnosis via either risk-stratification using molecular testing or surgical excision when diagnostic uncertainty remains. [1]